<p><strong>Abstract:</strong> ?ntroduction: Microangiopathic hemolytic anemia (MAHA) is a group of patients&nbsp; with a&nbsp; mortality that is rarely treated untreated.Aim: Our aim is to emphasize the need to recall the MAHA in differential diagnosis of patients&nbsp; with thrombocytopenia, especially those with end-organ involvement, which are presented in this study.At the same time to show that the rate of mortality in early&nbsp; diagnosis and treatment has decreased.Materials and methods: We retrospectively reviewed the&nbsp; cases that were diagnosed and treated and treated in the Internal Medicine Service between september 2017 and may 2019.A total of 15 patients were included in the study.From patients, first application; complete blood count, sedimentation, peripheral smear, direct coombs, CRP, coagulation tests and biochemical tests were performed.Also, before and after each plasmapheresis treatment; complete blood count, urea, creatine, LDH, indirect bilirubin levels.Findings: The mean age of the patients was 8/7 (53.3/46.6) and the mean age was 46.8(25-79).As a result of etiological classification of patients; 8 patients (53.3%) had TTP, 4 patients (%26.6 ) had vitamin B12 deficiency, 1 patient had systemi lupus erythematosus( %6.6), 1 patient (%6.6) was associated with complement, 1 patien&nbsp; (%6.6) had drug-releated.As a result of; the 15 patients included in the study, 11 patients (73.3%) were recovered, 1 patient (6.6%) died after discharge, and 4 patients (20%) died during follow, totally 5 (%33.3) patients died.</p>